Treatment of Chikungunya Virus Disease in the Chronic Phase

Patients with Chikungunya virus disease who progress to the chronic phase present a distinct clinical challenge. Management at this stage is phase-specific and directed at limiting ongoing tissue damage and improving long-term functional outcomes.

Clinical Scenario The clinical management of Chikungunya is based on the phase of the disease. In the chronic phase, the treatment objectives are to limit potential joint damage, decrease the functional and psychological impact, and improve the patient's quality of life.

Treatment Approach

Management in the chronic phase centres on a disease-modifying antimalarial agent used in combination with anti-inflammatory therapy. DMARDs are the mainstay of therapy for moderate to severe symptoms.

Full dosing, duration, and monitoring parameters are detailed in the structured protocol below.

Instant Access to Structured Evidence-Based Regimens

References

The clinical management of Chikungunya is based on the phase of the disease.

The treatment objectives in this phase of illness are to limit the potential joint damage, decrease the functional and psychological impact and improve the quality of life.

Hydroxychloroquine should be used in optimum doses for 8-12 weeks, along with NSAIDs.

DMARDs are the mainstay of therapy for moderate to severe symptoms.

View source ↗